Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
The refund notice posted Feb. 2 on the U.S. Health
…
While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.
Bayer gave the statement
…
EMD Serono today became the 21st pharmaceutical manufacturer to impose conditions on 340B pricing involving drug shipments to contract pharmacies.
Bayer announced conditions on 340B sales involving contract pharmacies earlier today. The companies’ announcements came two days after
…
Bayer Healthcare Pharmaceuticals starting March 1 is imposing limits on hospitals’ replenishment orders of 340B-priced drugs shipped to contract pharmacies. It said it is voluntarily letting 340B grantee covered entities continue to use multiple contract pharmacies to dispense 340B drugs.
…
Drug manufacturer Astellas will let 340B covered entities using “a compliant 340B inventory replenishment model” count accumulations of its antifungal Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, the company
…
The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.
BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent
…
Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.
Lilly was the first company to impose such conditions, starting with one drug in July 2020 then expanding to
…
Swiss eye care drug manufacturer Alcon is providing refunds for charges above 340B ceiling prices on 22 NDCs for varying sales periods from Q3 2019 through Q3 2022.
The U.S. Health Resources and Services Administration posted Alcon’s public notice about
…
Drug manufacturer Viatris will give 340B covered entities credits on requests for purchases of dozens of NDCs at higher than 340B ceiling price during the first 11 days of August, the company says in a notice on the U.S. Health
…*Sign up for news summaries and alerts from 340B Report